OKYO Pharma’s (OKYO) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of OKYO Pharma (NASDAQ:OKYO) in a report released on Wednesday, Benzinga reports. The firm currently has a $7.00 price objective on the stock. HC Wainwright also issued estimates for OKYO Pharma’s Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.38) EPS.

OKYO Pharma Stock Up 1.0 %

NASDAQ:OKYO opened at $1.02 on Wednesday. The firm’s 50-day moving average price is $1.04 and its 200-day moving average price is $1.25. OKYO Pharma has a 1-year low of $0.81 and a 1-year high of $2.12.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.